1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Ganga Pharmaceuticals Ltd.

Ganga Pharmaceuticals Ltd.

BBSE:GANGAPHARM
12.50
INR
+0.50
(+4.17%)
70.94MMarket Cap
Ganga Pharmaceuticals Ltd.
BSE:GANGAPHARM
(Bombay Stock Exchange)

Recent

price

12.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
6.63
6.47
7.41
7.52
8.28
7.58
5.85
6.13
6.37
5.66
5.45
4.78
- -
Revenue per Share
0.08
0.12
0.18
0.23
0.46
0.46
0.05
0.09
0.1
0.1
0.16
0.17
- -
Basic EPS, GAAP
- -
-2.62
0.01
-0.06
0.2
-0.78
-0.47
-0.55
-0.13
-2.66
-1.4
-2.28
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
6.49
11.82
12
12.24
12.69
13.18
13.23
13.32
13.42
14.58
14.75
14.06
14.06
Book Value per Share
6.49
11.82
12
12.24
12.69
13.18
13.23
13.32
13.42
14.58
14.75
14.06
14.06
Tangible Book Value per Share
4
4
4
4
4
4
4
4
4
5
5
6
6
Basic Weighted Avg Shares
27
26
30
31
34
31
24
25
26
27
26
28
- -
Sales/Revenue/Turnover
14.09
9.9
8.84
10.85
20.03
14.67
-0.87
-0.51
-1.99
0.31
-6.17
-0.54
- -
Operating Margin (%)
- -
- -
- -
1
1
1
1
1
1
- -
- -
1
- -
Depreciation Expense
- -
- -
1
1
2
2
- -
- -
- -
- -
1
1
- -
Net Income, GAAP
31.58
30.59
29.87
25.75
27.61
26
45.58
26
26.01
26.33
16.58
21.5
- -
Effective Tax Rate (%)
1.24
1.85
2.46
3.08
5.56
6.13
0.86
1.52
1.52
1.7
3
3.59
- -
Profit Margin (%)
11
34
26
22
24
28
30
32
33
46
53
63
63
Working Capital
15
13
11
9
7
6
7
9
6
4
2
1
1
LT Debt
26
48
49
50
52
54
54
54
55
71
71
83
83
Total Equity
- -
3.07
2.67
2.94
5.29
3.51
-0.16
-0.13
-0.52
0.08
-1.59
-0.13
- -
Return on Invested Capital (%)
- -
4.42
4.14
4.24
5.16
5.06
1.69
2.48
2.43
2.29
2.59
2.21
- -
Return on Capital (%)
- -
1.31
1.53
1.91
3.7
3.59
0.38
0.7
0.72
0.75
1.11
1.31
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
ST Debt
12
13
10
LT Borrowings
2
3
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5
6
6
Market Capitalization
49
86
71

Working Capital

INR

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
Total Current Assets
69
75
76
Cash, Cash Equivalents & STI
3
- -
1
Accounts Receivable, Net
9
10
9
Inventories
12
12
12
Total Current Liabilities
16
16
12
Payables & Accruals
- -
- -
- -
ST Debt
12
13
10
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.99%
9.7%
16.56%
Free Cash Flow
65.78%
449.49%
99.38%
Net Income, GAAP
29.63%
41.29%
28.48%
Sales/Revenue/Turnover
1.29%
3.63%
7.22%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
27
2025
- -
- -
26
2026
- -
- -
28

Semi-annual Earnings Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.1
2025
- -
- -
0.16
2026
- -
- -
0.17

Semi-annual Dividends Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Ganga Pharmaceuticals Limited manufactures, markets, and distributes a comprehensive range of Ayurvedic medicines and herbal products targeting various health conditions. Its main product offerings include Ayurvedic medicines for acidity, antidandruff, antioxidants, blood purifiers, skin disorders, constipation, cough and cold, diarrhea, dental care, ear care, hair care, indigestion, kidney stone treatment, liver disorders, sleep inducers, and weight management. The company additionally produces iron tonics, female tonics, rejuvenation tonics, treatments for hemorrhoids and piles, joint pain remedies, and a variety of herbal cosmetic products. Founded in 1989 and headquartered in Mumbai, India, the company has expanded its marketing and distribution footprint domestically and internationally with ties in Saudi Arabia, Dubai, Italy, Romania, and Russia. Recent company developments include continued focus on Ayurvedic product manufacturing and distribution amid stable operations, with no major corporate restructuring or acquisitions publicly reported in the last two years. The company remains engaged in maintaining quality and expanding market reach through strategic marketing alliances and its established product portfolio that supports traditional Ayurvedic health care needs, strengthening its position in the consumer staple and household products segments primarily in India with growing export activities. Its executive management includes Bharat Brijmohan Sharma as Managing Director and it operates in the pharmaceuticals and allied products sector focused on Ayurveda.